BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210629
DTEND;VALUE=DATE:20210702
DTSTAMP:20260515T190244
CREATED:20210301T091950Z
LAST-MODIFIED:20210301T091950Z
UID:29192-1624924800-1625183999@www.pharmajournalist.com
SUMMARY:6th Microbiome Movement - Drug Development Summit
DESCRIPTION:Close the Clinical Gap\, Discover the Next Generation of Microbiome-based Therapeutics\, and Establish New Partnerships to Accelerate Your Research \nThe advancing scientific and clinical landscape mixed with the high-quality audience that we bring together has made this the must attend conference for those translating microbiome science into clinically successful therapeutics. \nThere is increased excitement around this years’ discussion; the community is now closer than ever to the first approved and commercially available microbiome-based therapeutic\, key functions are beginning to be understood and the number of clinical candidates are increasing. However\, there still remains an abundance of significant hurdles that must be overcome in order for continued success to be seen within the microbiome field. We are proud to bring together those at the forefront of tackling those challenges and is once again the centre of the 6th Microbiome Movement – Drug Development Summit. \n \nThe Microbiome Movement will provide the perfect opportunity for a collaborative approach between the biopharmaceutical and academic communities in order to pursue the causal role of the microbiome in disease and develop a new generation of microbiome-targeted therapeutics with predictable modes of action and consistent clinical outcomes. \nFrom understanding microbiome functionality\, leveraging lessons from clinical development and scaling manufacturing processes\, through to leveraging microbiome biomarkers for patient stratification and diagnostics\, our discussion will cover the latest scientific findings and industry updates from the end-to-end development of microbiome therapeutics. \nThere is still so much we can continue to do to make this complex science a clinical reality that improves the lives of patients\, and we hope that you can join this years’ discussion to help towards the development of effective treatments across a range of indications and push microbiome products closer to commercialization. \nTo know more about 6th Microbiome Movement – Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/6th-microbiome-movement-drug-development-summit/
LOCATION:Virtual
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210629
DTEND;VALUE=DATE:20210702
DTSTAMP:20260515T190244
CREATED:20210309T092319Z
LAST-MODIFIED:20210309T092319Z
UID:29289-1624924800-1625183999@www.pharmajournalist.com
SUMMARY:Induced Proximity-Based Drug Discovery Summit
DESCRIPTION:Since the start of the 20th century\, there have been three major waves of innovation in drug discovery. We are now at the start of a fourth wave\, multispecific medicines\, that will pave the way for new treatments aimed at thousands of disease targets currently viewed as “undruggable”. By inducing proximity between two or more proteins\, multispecifics can harness the power of biology to go well beyond what conventional drugs can achieve. \n \nAs such\, the inaugural Induced Proximity-Based Drug Discovery Summit arrives as the dedicated scientific and networking forum for large pharma\, innovative biotech and research institutes to seize the endless potential of induced proximity- based drug discovery strategies to develop novel therapies for paradigm changing multispecific drugs of the future. \nJoin 100+ thought leaders of Chemically Biology\, Screening Biology and Molecular Biology from the likes of Amgen\, Ranok Therapeutics\, Proxygen and more at the Induced Proximity- Based Drug Discovery Summit to advance your knowledge\, differentiate your pipelines and be at the forefront of this new wave of innovation that will revolutionize drug discovery as currently known. \nTo know more about Induced Proximity-Based Drug Discovery Summit please click here.
URL:https://www.pharmajournalist.com/event/induced-proximity-based-drug-discovery-summit/
LOCATION:EST | Digital
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210629
DTEND;VALUE=DATE:20210702
DTSTAMP:20260515T190244
CREATED:20210312T075616Z
LAST-MODIFIED:20210312T080030Z
UID:29331-1624924800-1625183999@www.pharmajournalist.com
SUMMARY:JAK Inhibitors Drug Development Summit
DESCRIPTION:Returning to the digital stage this summer\, the 2nd JAK Inhibitors Drug Development Summit brings you the only dedicated JAK inhibitor conference that will allow you to utilize the knowledge of the greatest minds and thought leaders within the realms of the JAK pathway across dermatology\, rheumatology\, gastroenterology\, oncology and hematology. \nFocusing on optimized selectivity\, drug-drug interactions\, safety and efficacy challenges\, this summit will give you the insight to successfully translate and develop the next generation of superior JAK inhibitors. \nEnsure you attend this conference to learn\, to network and to strengthen your pipeline\, and implement the right clinical strategy.
URL:https://www.pharmajournalist.com/event/jak-inhibitors-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210630
DTEND;VALUE=DATE:20210702
DTSTAMP:20260515T190244
CREATED:20210331T084111Z
LAST-MODIFIED:20210331T110431Z
UID:29602-1625011200-1625183999@www.pharmajournalist.com
SUMMARY:3rd Cell Engager Summit
DESCRIPTION:The 3rd Annual Cell Engager Summit is the only industry-led forum dedicated to developing multi-specific cell engaging therapies in liquid and solid tumor indications\, accelerating early discovery innovation into the clinic. \nThis forum comes at a critical point for the cell engager field as the success observed in the hematological field has not been obtained with solid tumors yet. Preclinical and early clinical data for cell engagers targeting solid tumors have been hugely promising. \nIf you are part of a research team that is looking to accelerate the approval of cell engager therapies\, then this conference has been curated with you in mind. \nBelow are a few highlights you won’t want to miss: \n\nDrive efficacy in solid tumors with solid tumor targets addressed by Roche\, Amgen\, Pfizer\, Merus\, andCompass Therapeutics\nModulate the immune system to drive efficacy via co-stimulatory targets in solid tumors with Xencor\, Harbour Biomed\, Crescendo Biologics\, Pieres\,and Aptevo\nHarness the power of the innate system for cell engagers and overcome the tumor microenvironment with Merck\, Lava Therapeutics\, Verseau Tx\, andoNKo-Innate\nImproving the therapeutic window of cell engagers – addressing toxicity\, half-life\, and CRS withAmunix\, Synaffix\, Revitope\, and TeneoBio\n\nTo know more about 3rd Cell Engager Summit please click here.
URL:https://www.pharmajournalist.com/event/3rd-cell-engager-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210713
DTEND;VALUE=DATE:20210716
DTSTAMP:20260515T190244
CREATED:20210302T095204Z
LAST-MODIFIED:20210302T095204Z
UID:29214-1626134400-1626393599@www.pharmajournalist.com
SUMMARY:ARDS Drug Development Summit 2021
DESCRIPTION:The inaugural ARDS Drug Development Summit will bring 60+ biopharma leaders together to discover how the rise of SARS-CoV-2 ARDS\, emergence of novel targets\, and the past 12 months of unprecedented global focus on ARDS research has transformed this graveyard of drug development failures into a starting point for the next generation of therapeutics addressing not just ARDS\, but broader\, systemic inflammation. \nVirtually uniting dedicated and experienced industry experts from Aqualung\, Bone Therapeutics\, Boehringer Ingelheim\, Athersys and more\, this trailblazing new meeting will help you overcome your most urgent drug development challenges.
URL:https://www.pharmajournalist.com/event/ards-drug-development-summit-2021/
LOCATION:Virtual
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210713
DTEND;VALUE=DATE:20210716
DTSTAMP:20260515T190244
CREATED:20210312T065852Z
LAST-MODIFIED:20210312T065852Z
UID:29308-1626134400-1626393599@www.pharmajournalist.com
SUMMARY:mRNA Based Therapeutics Summit
DESCRIPTION:The mRNA-Based Therapeutics Summit will unite the world leaders developing mRNA therapeutics to discuss learnings\, challenges and future directions concerning translation and manufacturing of your novel mRNA modality. From mRNA vaccine development for infectious disease and oncology\, effective mRNA gene therapies and novel delivery strategies\, we bring to you an all-inclusive platform dedicated to accelerating successful translation of mRNA into a transformative class of medicines.  \nTo know more about mRNA Based Therapeutics Summit please click here.
URL:https://www.pharmajournalist.com/event/mrna-based-therapeutics-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210713
DTEND;VALUE=DATE:20210716
DTSTAMP:20260515T190244
CREATED:20210312T072425Z
LAST-MODIFIED:20210312T072425Z
UID:29325-1626134400-1626393599@www.pharmajournalist.com
SUMMARY:Non-Small Cell Lung Cancer Drug Development Summit
DESCRIPTION:The Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit is the definitive industry-led forum for drug development in the largest solid tumor indication. \nThis is a strategic conference designed to bring drug development teams together to address critical challenges surrounding therapeutic potency\, tumor resistance and relapse and expanding the clinical utility of targeted and immuno-therapies\, either in combination or monotherapies. \n \nAs checkpoint inhibitors are on the brink of entering the perioperative setting and the approval of novel bispecifics with dual oncogenic targeting\, this forum will enable you to see a full picture of the clinical trial landscape and identify what MoAs and targets future biopharma investment will be put towards. \nJoin Global Innovators To: \n\nLeverage the knowledge gained from the current EGFR-TKI successes to implement it into strategies for improvement\, best application strategies and potential combination partners with AstraZeneca\, Puma Biotechnology\, Cullinan Oncology and Takeda\nUnravel the potentials of targeting currently untreatable acquired resistances through small molecules and biologics to develop novel agents against mutations with AbbVie\, Merus\, Black Diamond\, AOM Biosciences and Mirati Therapeutics\nDive into the exciting advancements in the NSCLC rare mutations space\, with the novel therapies in targeting BRAF\, NGR1 fusions and HER2 with Kinnate Biopharmaceuticals\, Elevation Oncology and Boeringer Ingelheim\nHarness the power of the immune system to treat NSCLC by delving into the current best\, novel targets and combination strategies to improve patent outlook with Merck & Co\, Immutep\, BerGenBio and Bristol-Myers Squibb\nAdvance the efficacy of companion diagnostics and look to the future of early disease detection\, application and differences in patient populations and how combination therapy can best be exploited to beat this drastically unmet clinical need with UAMS\, Takeda\, Novartis\, BloodPAC and Amgen\nA deep-dive workshop explores how to utilize EGFR-targeting in solid tumors outside of NSCLC with Maverick Therapeutics\, Black Diamond Therapeutics and Harvard Medical School\n\nNetwork with 100+ executive biopharma leaders over 3-days of comprehensive insights to uncover the latest industry knowledge on the molecular heterogeneity of lung cancer\, the implications for therapeutic design when considering acquired resistance and optimal application of new drugs in the clinic.
URL:https://www.pharmajournalist.com/event/non-small-cell-lung-cancer-drug-development-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210714
DTEND;VALUE=DATE:20210716
DTSTAMP:20260515T190244
CREATED:20210514T083527Z
LAST-MODIFIED:20210514T084615Z
UID:30155-1626220800-1626393599@www.pharmajournalist.com
SUMMARY:GxP Cloud Compliance Summit
DESCRIPTION:Develop & implement your practical roadmap to migrate your GxP regulated applications to the cloud with regulatory\, security & partner selection guidance.  \nEstablish robust documentation practices to maintain CFR 11 compliance\, accurately assess data security risks for migrating to cloud infrastructure & select the right partner to ensure sustained continuous compliance. \nNothing is more important in the pharmaceutical and life sciences industries than patient safety and meeting regulations. This past year and the global disruption have highlighted how life sciences organizations need to respond to radical shifts through digitization. The 2nd GxP Cloud Compliance Summit will return to discuss the next steps following initial feasibility study and implementation – designed to help you achieve GxP regulated security\, privacy\, transparency and compliance at any scale when migrating to the cloud. \nWith 18 trailblazing stories from AbbVie\, Orchard Therapeutics\, AWS\, USDM\, Chef/Progress\, we will share practical takeaways from CFR21 part 11 to mapping out data migration to selecting the right cloud providers. Across 2 days\, you will gain the tools to streamline processes\, facilitate on demand scalability\, increase efficiency and reduce costs. \nThis is the only dedicated industry-led meeting focused on GxP cloud adoption in the life sciences industry\, join us this July to learn how to overcome the barriers of GxP cloud compliance\, increase knowledge for data-powered business and empower collaboration between your organization and platform partners – providing a much more efficient operation and effective infrastructure to support your research and clinical activities. \nFind out more >>> https://ter.li/xv45we
URL:https://www.pharmajournalist.com/event/gxp-cloud-compliance-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210719
DTEND;VALUE=DATE:20210722
DTSTAMP:20260515T190244
CREATED:20210312T071709Z
LAST-MODIFIED:20210312T071709Z
UID:29322-1626652800-1626911999@www.pharmajournalist.com
SUMMARY:2nd Gene Therapy for Neurological Disorders Europe
DESCRIPTION:Returning digitally in 2021\, the 2nd Annual Gene Therapy for Neurological Disorders Europe meeting will possibly be your last chance to attend a European meeting without the airmiles! \nFocusing on the industry’s challenges of developing and delivering gene therapies to the CNS and bringing fresh faces and emerging companies into the conversation\, this is not one to miss as you seek to accelerate the development of your neurological gene therapy. \nDiscover the latest neurological targets\, familiarise yourself with the European landscape\, and debate and discuss with the leading minds of the field from the likes of UCB\, Lysogene\, UniQure and AskBio\, as they seek to harness the opportunity and move from rare to common disorders such as Alzheimer’s\, Parkinson’s and epilepsy. \n \nFocusing on translation and ‘what’s new’ in the gene therapy for neurological disorders field\, this year’s 3-day agenda has been developed alongside neurological experts from AskBio\, Handl Therapeutics\, Novartis and Spark Therapeutics to capture the most pressing challenges and new opportunities facing the field. \nDiscussing rare to common neurological disorders\, attend the digital meeting in July to: \n\nHear the latest clinical updates from the most advanced companies to inform your future strategies\nDiscover the novel neurological targets being pursued by gene therapy developers to learn of the latest CNS opportunities\nDiscuss how to optimise the use of preclinical models and biomarkers for improved translation and reduced risk to patients\nAsk the European Medicines Agency questions related to the specific regulatory challenges of designing trials for both rare and common disorders\nWeigh up the advantages and disadvantages of established and novel routes of administration for CNS gene therapy delivery\nRaise questions to the neurosurgeons at the forefront of neurosurgical delivery and hear their thoughts on the technical challenges facing different programs\nBe a part of the debate and discussion related to measuring and overcoming CNS immunogenic responses\n\nDon’t miss your opportunity to benchmark against your competitors\, hear the state of the art technology advances and research in the field\, and make new connections at the last digital European meeting\, to revolutionise the development and delivery of your neurological gene therapy.
URL:https://www.pharmajournalist.com/event/2nd-gene-therapy-for-neurological-disorders-europe/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210720
DTEND;VALUE=DATE:20210722
DTSTAMP:20260515T190244
CREATED:20210208T085452Z
LAST-MODIFIED:20210208T085452Z
UID:28862-1626739200-1626911999@www.pharmajournalist.com
SUMMARY:In-House Impact: Life Sciences
DESCRIPTION:In-House Impact: Life Sciences is a new type of forum\, designed for and by legal leaders in the Life Sciences\, to help legal teams move from enterprise defenders to enablers of innovation and cross-functional competency. \nThis conference isn’t just unique in offering an industry-specific platform for the most progressive legal leaders to maximize their own business value; it’s also unique in that it rips up the rulebook of traditional conferences. \nWe guarantee that your time out of the office and money are well spent. With thought-provoking case studies\, action-led discussions and ensuring every story shared is evidenced by the business improvement it delivers\, we’ve no doubt this strategic discussion will leave you feeling inspired to make big change. \nTo know more about In-House Impact: Life Sciences please click here.
URL:https://www.pharmajournalist.com/event/in-house-impact-life-sciences/
LOCATION:Exclusive Virtual Conference
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210720
DTEND;VALUE=DATE:20210723
DTSTAMP:20260515T190244
CREATED:20210322T111844Z
LAST-MODIFIED:20210322T111844Z
UID:29474-1626739200-1626998399@www.pharmajournalist.com
SUMMARY:Cell-Mediated Therapies for Infectious Disease Summit
DESCRIPTION:In the fight against emerging coronavirus variants\, the need for long-lasting immunity is greater than ever… which is why the field is looking beyond antibodies and turning to T cells. \nThe Cell-Mediated Therapies for Infectious Disease Summit is the first industry-dedicated meeting to understand and stimulate the immune cell response to develop long term immune memory to infectious disease pathogens. See more – https://ter.li/bo7qq7 \nJoin over 80 industry and academic leaders pioneering this new paradigm of research\, and for the first time discuss novel advances in t-cell epitope-directed vaccines\, as well as CAR-T\, TCR and NK cell therapies designed to provoke durable immunity. \nWith strategic insight and clinical advances shared from Gilead\, Merck\, Vaccibody\, TScan Therapeutics and more\, join the discussion to assess: \n\nBioinformatic tools to identify immunogenic targets\nVaccine design and delivery to trigger strong T cell responses\nBridge the gap from translatable preclinical models to IND approval\n\nLeave this meeting with a greater understanding of next-generation approaches to target\, prevent and cure HIV\, EBV and SARS-CoV-2 infection. \nSee more – https://ter.li/bo7qq7
URL:https://www.pharmajournalist.com/event/cell-mediated-therapies-for-infectious-disease-summit/
LOCATION:Digital | EDT
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210720
DTEND;VALUE=DATE:20210723
DTSTAMP:20260515T190244
CREATED:20210414T091907Z
LAST-MODIFIED:20210414T091907Z
UID:29789-1626739200-1626998399@www.pharmajournalist.com
SUMMARY:Next Generation Food Allergy Drug Development
DESCRIPTION:In the context of dramatically increasing food allergy incidence and a breakthrough approval in the field\, the Next Generation Food Allergy Drug Development Summit will unite large pharma and innovative biotechs to overcome the unique drug development challenges involved in turning promising food allergy biologics into clinical and commercial realities. \nJoin us to investigate the latest technological innovations\, benchmark against your peers\, build global connections and streamline your drug development pipelines for food allergy\, with insights being shared from a range of companies and institutions including Prota Therapeutics\, Allergy Therapeutics\, Intrommune\, Vedanta Biosciences and University of North Carolina. \nTo know more about Next Generation Food Allergy Drug Development please click here.
URL:https://www.pharmajournalist.com/event/next-generation-food-allergy-drug-development/
LOCATION:Online | EDT
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR